date:Feb 25, 2014
were disclosed. Officials with Elanco said the acquisition will strengthen Elancos presence in the vaccine segment, broaden the company's product offerings and significantly augment Elancos vaccine manufacturing capabilities.
Effectively competing in the animal vaccine segment is a cornerstone of Elancos long-term strategy and is one more way we will expand the value we create for customers, said Jeff Simmons, senior vice president of Eli Lilly and Co. and president of Elanco Animal Health. Th